Loading stock data…
GRAL
$61.26-0.38 (-0.62%)
Pre-Market$61.90+0.64 (+1.04%)· Last close May 11
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GRAIL, Inc. in the Healthcare sector is trading at $61.26. The stock is currently 48% below its 52-week high of $118.84, remaining 9.2% below its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why GRAL maintains its current current market pressure. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$61.26
Potential Upside
5%
Whystock Fair Value$64.32
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$66.86+9.1%
Range$56.00 – $80.00
Fundamentals
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.16B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-15.84%
Volume
Today's trading volume
575,828
Recent News
How The GRAIL (GRAL) Narrative Is Shifting After NHS Galleri Results And Reimbursement Questions
GRAIL’s modelled fair value sits at US$67.71, with recent research showing a wide range of price target moves, from cuts to around US$60 to fresh initiations with triple digit targets. These shifts align with the split in views after the NHS Galleri readout and ongoing questions around reimbursement, set against a very large estimated multi cancer early detection market of about US$70b. As you read on, you will see how these moving targets contribute to the evolving analyst story around the...
GRAIL Q1 Earnings Call Highlights
GRAIL (NASDAQ:GRAL) reported first-quarter fiscal 2026 results highlighting higher test volumes and screening revenue growth, alongside updates on its FDA premarket approval (PMA) review and upcoming clinical data presentations. Executives also discussed commercial partnerships, electronic health re
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Look At GRAIL (GRAL) Valuation After New Galleri Integrations With Epic Junction And Superpower
GRAIL (GRAL) is back in focus after a run of integration deals that plug its Galleri multi cancer early detection blood test into Epic electronic health records, Junction’s diagnostic infrastructure, and Superpower’s preventive health platform. See our latest analysis for GRAIL. Those integration headlines come amid a sharp reset in sentiment, with a 1 day share price return of a 4.06% decline and a 90 day share price return of a 54.42% decline, even as the 1 year total shareholder return...
GRAIL Partners With Epic to Broaden Galleri Test Access Across US
GRAIL partners with Epic to embed its Galleri cancer test into EHRs, expanding access across nearly 450 health systems and streamlining clinical workflows nationwide.